Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07072195
PHASE2

A Study of AMC6156 in People With Sarcopenia

Sponsor: Animuscure Inc.

View on ClinicalTrials.gov

Summary

This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.

Official title: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2025-07-01

Completion Date

2026-06

Last Updated

2025-07-29

Healthy Volunteers

No

Interventions

DRUG

AMC6156 0.1mg

Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.

DRUG

AMC6156 0.3mg

Oral administration of AMC6156 in tablet form at a dose of 0.3 mg once daily for 12 weeks.

DRUG

AMC6156 1.0mg

Oral administration of AMC6156 in tablet form at a dose of 1.0 mg once daily for 12 weeks.

DRUG

Placebo

Oral administration of placebo tablets matching AMC6156 in appearance, once daily for 12 weeks.

Locations (4)

CHA Bundang Medical Center

Seongnam-si, Gyeonggi-do, South Korea

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea

Seoul National University Hospital

Seoul, Seoul, South Korea